DrugPatentWatch Database Preview

Details for Patent: 5,965,525

« Back to Dashboard

Which drugs does patent 5,965,525 protect, and when does it expire?

Patent 5,965,525 protects ERAXIS and is included in one NDA.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 5,965,525

Title:	Cyclic peptide antifungal agents
Abstract:	Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R and R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s):	Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/449,056
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 5,965,525
Patent Claim Types: see list of patent claims	Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 5,965,525

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-001	Feb 17, 2006		RX	Yes	Yes			Y	Y		TREATMENT OF FUNGAL INFECTIONS
Vicuron	ERAXIS	anidulafungin	POWDER;INTRAVENOUS	021632-002	Nov 14, 2006		RX	Yes	Yes			Y	Y		TREATMENT OF FUNGAL INFECTIONS

International Family Members for US Patent 5,965,525

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	217635
Australia	3534193
Australia	6552996
Australia	689391